ArticleFrontiers in public health2026
Strengthening health technology assessment in Greece: industry-identified barriers and recommendations.
Article in Frontiers in public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The Post-Authorisation Maze: Mapping of European Pharmaceutical Market Access Pathways in the Early JCA Era.Journal of market access & health policy · 2026Article
- From Variant Interpretation to Biomarker Translation: Multi-omics Integration in Inherited Neuromuscular Diseases.Human mutation · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This qualitative study explores pharmaceutical industry stakeholders' perspectives on Health Technology Assessment (HTA) in Greece and its perceived implications for public reimbursement decision-making. Since 2018, the Greek Committee for the Evaluation and Reimbursement of Medicines for Human Use has played a central role in recommending medicines for inclusion in the national reimbursement list. Understanding the views of a key HTA stakeholder group provides insight into how the post-2018 HTA and negotiation pathway is experienced in practice and how it is perceived to support timely, evidence-informed decision-making. Methods: Seventeen senior Market Access executives from pharmaceutical companies were recruited through purposive sampling and interviewed using a semi-structured interview guide. Data were analyzed using thematic analysis, with iterative coding and theme refinement to support analytical rigor. Results: Nine themes were identified, reflecting participants' concerns regarding the HTA Committee's staffing capacity, technical expertise, and transparency. Additional challenges described by participants included legislative misalignment, bureaucratic inefficiencies, limited stakeholder engagement, and delays associated with complex and multi-criteria assessment processes. Additionally, participants proposed fifteen (15) targeted recommendations aimed at strengthening HTA implementation in Greece. Conclusion: The findings provide stakeholder-informed insights relevant for policymakers seeking to enhance Greece's HTA framework. As perceived by participants, priorities include strengthening governance and independence, addressing capacity and skills gaps through structured development, clarifying evaluation criteria, increasing transparency, enabling more meaningful stakeholder participation, and advancing digitalization. These improvements have the potential to support more consistent, evidence-informed reimbursement decisions, facilitate timely access to innovative therapies, and contribute to healthcare system sustainability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.